(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.
Longeveron's earnings in 2025 is -$18,688,000.On average, 3 Wall Street analysts forecast LGVN's earnings for 2025 to be -$18,112,594, with the lowest LGVN earnings forecast at -$18,214,290, and the highest LGVN earnings forecast at -$17,910,719.
In 2026, LGVN is forecast to generate -$14,116,075 in earnings, with the lowest earnings forecast at -$18,062,504 and the highest earnings forecast at -$10,169,645.